X4 Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, X4 Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 2 currently recruiting 6 completed early-phase tilt top decile by trial count

X4 Pharmaceuticals: 11 sponsored US clinical trials, 2 recruiting.

X4 Pharmaceuticals sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is WHIM Syndrome, with 1 trials.

Top-decile sponsor footprint

X4 Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NCT06858696
RECRUITING Phase 3

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297
ACTIVE NOT RECRUITING Phase 3

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03995108
COMPLETED Phase 1

Drug-Drug Interaction Potential of Mavorixafor

NCT06914869
COMPLETED Phase 1

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

NCT04154488
COMPLETED Phase 1

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

NCT04274738
TERMINATED Phase 1

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

NCT02923531
COMPLETED Phase 2

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03005327
COMPLETED Phase 1

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

NCT02823405
COMPLETED Phase 1

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

NCT02667886
TERMINATED Phase 1

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

NCT02680782

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 1
Phase 3 2

Therapeutic Areas

WHIM Syndrome 1
Waldenstrom's Macroglobulinemia 1
Hepatic Insufficiency 1
Neutropenia 1
Melanoma 1

What is open in the X4 Pharmaceuticals pipeline

2 recruiting of 11 indexed (18% open); 6 completed (55%).

Phase mix: 2 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: WHIM Syndrome (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

X4 Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

X4 Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10.910.91111.1 0%5%10%15%20% Total trials Recruiting share X4 PharmaceuticalsAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeBurke Medical Research InstituteGrand Valley State UniversityImunonInventisBio Co.
X4 Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

X4 Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this X4 Pharmaceuticals page

11 registered trials is a research-attention snapshot, not an endorsement of X4 Pharmaceuticals or any single study.

  • 2 of X4 Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • WHIM Syndrome is the condition X4 Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See WHIM Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

X4 Pharmaceuticals pipeline card: 11 registered trials from official public datasets.Report a data error.